CAJ | 학술논문

目的：探讨奥氮平预防化疗所致爆发性呕吐的疗效与安全性。方法收集2012年7月至2013年6月在化疗第1周期发生爆发性呕吐的36例恶性肿瘤患者，于第2周期化疗前给予常规预防止吐及口服奥氮平（奥氮平10mg/次，每日1次，d1～d3）预防爆发性呕吐，采用CTCAE标准对呕吐程度进行评分，比较联合奥氮平预防前后患者恶心呕吐评分的差异。结果36例患者联合奥氮平预防后恶心呕吐评分较联合前明显下降（10?1±0?9 vs．18?2±1?2，P＝0?032），其中47?2％（17/36）患者未再发生呕吐，75?0％（9/12）的女性患者未再出现爆发性呕吐。36例恶性肿瘤患者采用奥氮平治疗的止吐有效率为80?0％。主要相关毒副反应为头晕和乏力，发生率分别为36?1％和30．6％。结论奥氮平能有效降低化疗相关爆发性呕吐的发生率，改善恶性肿瘤患者化疗后的恶心呕吐。
목적：탐토오담평예방화료소치폭발성구토적료효여안전성。방법수집2012년7월지2013년6월재화료제1주기발생폭발성구토적36례악성종류환자，우제2주기화료전급여상규예방지토급구복오담평（오담평10mg/차，매일1차，d1～d3）예방폭발성구토，채용CTCAE표준대구토정도진행평분，비교연합오담평예방전후환자악심구토평분적차이。결과36례환자연합오담평예방후악심구토평분교연합전명현하강（10?1±0?9 vs．18?2±1?2，P＝0?032），기중47?2％（17/36）환자미재발생구토，75?0％（9/12）적녀성환자미재출현폭발성구토。36례악성종류환자채용오담평치료적지토유효솔위80?0％。주요상관독부반응위두훈화핍력，발생솔분별위36?1％화30．6％。결론오담평능유효강저화료상관폭발성구토적발생솔，개선악성종류환자화료후적악심구토。
Objective To evaluate the efficacy and safety of olanzapine in prevention of breakthrough chemotherapy-induced vomiting in cancer patients receiving highly emetogenic chemotherapy. Methods Thirty-six cancer patients with chemotherapy related breakthrough vomiting in the first cycle were enrolled in this study. These patients were given olanzapine(10mg once daily, d1-d3)oral-ly before the second cycle of chemotherapy to prevent explosive vomiting. The nausea and vomiting of patients were scored according to the national cancer institute common terminology criteria for adverse events. The test was used to compare the differences of vomiting scores before and after receiving olanzapine. Results The vomiting scores of the 36 cases were significantly decreased (10?1±0?9 vs. 18?2±1?2, P=0?032) after combined with olanzapine in prevention. 47?2%(17/36) of the patients no longer had explosive vomiting after receiving olanzapine and 75?0% ( 9/12) of women patients no longer had vomiting after receiving olanzapine. The effective rate of olanzapine in prevention of vomitting was 80?0%. The main related side effects were dizziness and fatigue, and the incidences were 36?1% and 30?6%, respectively. Conclusion Olanzapine can effectively reduce the incidence of chemotherapy related breakthrough vomiting, and release the symptom of nausea and vomiting in cancer patients.